Provectus Pharmaceuticals Inc., of Knoxville, Tenn., completed patient accrual and treatment of subjects in its Phase I trial of PV-10 for liver cancer. The study involved six subjects with cancer metastatic to the liver or with recurrent liver cancer, with the goal of determining the safety and tolerability of a single intralesional injection of PV-10.